BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 31385048)

  • 1. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.
    Zech CJ; Ba-Ssalamah A; Berg T; Chandarana H; Chau GY; Grazioli L; Kim MJ; Lee JM; Merkle EM; Murakami T; Ricke J; B Sirlin C; Song B; Taouli B; Yoshimitsu K; Koh DM
    Eur Radiol; 2020 Jan; 30(1):370-382. PubMed ID: 31385048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus report from the 9
    Koh DM; Ba-Ssalamah A; Brancatelli G; Fananapazir G; Fiel MI; Goshima S; Ju SH; Kartalis N; Kudo M; Lee JM; Murakami T; Seidensticker M; Sirlin CB; Tan CH; Wang J; Yoon JH; Zeng M; Zhou J; Taouli B
    Eur Radiol; 2021 Aug; 31(8):5615-5628. PubMed ID: 33523304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management.
    Taouli B; Ba-Ssalamah A; Chapiro J; Chhatwal J; Fowler K; Kang TW; Knobloch G; Koh DM; Kudo M; Lee JM; Murakami T; Pinato DJ; Ringe KI; Song B; Tabrizian P; Wang J; Yoon JH; Zeng M; Zhou J; Vilgrain V
    Eur Radiol; 2023 Dec; 33(12):9152-9166. PubMed ID: 37500964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
    AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
    Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
    Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging.
    Merkle EM; Zech CJ; Bartolozzi C; Bashir MR; Ba-Ssalamah A; Huppertz A; Lee JM; Ricke J; Sakamoto M; Sirlin CB; Ye SL; Zeng M
    Eur Radiol; 2016 Mar; 26(3):674-82. PubMed ID: 26070500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.
    Li J; Wang J; Lei L; Yuan G; He S
    Eur Radiol; 2019 Dec; 29(12):6519-6528. PubMed ID: 31250172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases.
    Kim DH; Choi SH; Kim SY; Kim MJ; Lee SS; Byun JH
    Radiology; 2019 Jun; 291(3):651-657. PubMed ID: 30990381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI.
    Palm V; Sheng R; Mayer P; Weiss KH; Springfeld C; Mehrabi A; Longerich T; Berger AK; Kauczor HU; Weber TF
    Cancer Imaging; 2018 Mar; 18(1):9. PubMed ID: 29490696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
    Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
    Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.